Earn rewards for your opinion on lab products.

Get exclusive insights into life science trends.

Stay up to date on research news.

Targeted nanoparticle delivery provides boost for diabetes transplant
January 20, 2022 -- Delivering immunosuppressant treatment via targeted nanoparticles could open the door to a long-lasting cure for type 1 diabetes. Transplanting insulin-producing cells is a promising approach to treat the disease; however, it is plagued by issues of immune rejection. In a new study, published January 17 in Nature Nanotechnology, mice treated with a reengineered therapy could tolerate a transplant for much longer with fewer side effects. Read More
Developments in cell therapy boost potential for autoimmune disease treatments
January 19, 2022 -- Healthcare leaders are working together to change the therapeutic landscape for autoimmune diseases, which are often due to unknown causes, according to Cell and Gene Therapy Business Outlook, a sister publication of ScienceBoard. Atara Biotherapeutics, Kyverna Therapeutics, and the National Institutes of Health are a few organizations that are dedicated to finding treatments for patients with limited options. Read More
Do advanced therapies have a place in women's health?
January 18, 2022 -- Change may be on the horizon for the traditionally competitive and underinvested field of women's health, according to scientific experts in the field. With increased awareness, fast-paced innovation, and appropriate investment, the sector is ripe for progress. ScienceBoard spoke with Martin Lehr, CEO of Context Therapeutics, as part of Biotech Finance Month 2022. Read More
How biotech startups can secure funding, according to investors
January 17, 2022 -- What are strategies that emerging biotech companies can use to attract investors and secure funding that supports the development of their programs and technology? A panel of investors and finance professionals discussed the challenges and opportunities during the virtual Biotech Showcase 2022 event in a session titled "Early Seed Financing." Read More
ARM update points to strong 2022 for cell and gene therapy industry
January 14, 2022 -- Despite a turbulent investment year, the cell and gene therapy space continued to innovate and develop at an extraordinary speed, according to the "Cell & Gene State of the Industry Briefing," which was delivered on January 11 by the Alliance for Regenerative Medicine (ARM) in partnership with Biotech Showcase. Read More
CAR T cells produced in vivo may treat cardiac injury
January 13, 2022 -- New evidence suggests that immunotherapy could have the potential to temporarily reprogram patients' immune cells to attack a specific target via a single injection of mRNA. The study, published in Science, could lead to a new treatment for heart failure. Read More
Critical step identified in immune system response could lead to new treatments
January 12, 2022 -- New research has identified a crucial protein that controls the immune system's release of a key factor in fighting infections. The study, published in the journal Nature Communications on January 10, found that the MNDA protein is necessary for white blood cells to produce a type of interferon. This discovery could lead to new drugs to help fight infections or treat autoimmune conditions. Read More
How COVID-19 has shed light on importance of biotech tools, health equity
January 11, 2022 -- As the world enters the third year of the COVID-19 pandemic, it is clear that the virus has taught humanity some very tough lessons, but there have also been significant scientific advances. A panel explored the current challenges facing the industry, along with the silver linings, on January 10 at Biotech Showcase 2022. Read More
Rare disease treatments continue to advance alongside gene therapies
January 10, 2022 -- Rare diseases represent an underserved and frequently overlooked area in healthcare. As a result, funding for research in these diseases is often limited. However, many of these diseases are fatal or highly impair a patient's quality of life. According to a recent report from Cell and Gene Therapy Business Outlook, a sister publication of ScienceBoard, some institutions are focusing their efforts in the area of rare diseases. Read More
Meet and greet: SITC 2021
January 7, 2022 -- The Society for Immunotherapy of Cancer (SITC) 2021 meeting was an impactful event featuring the latest scientific and medical innovations in the field of immuno-oncology. These advances would not be possible if it were not for the dedicated professionals who work tirelessly to advance science's understanding of human health. Read More
Battle royale: Self-cloaking virus vs. regenerating bacteria
January 7, 2022 -- Which one is more likely to win in a fight: a self-cloaking virus or regenerating bacteria? These two groups of microbes can wreak havoc on the human body, albeit in vastly different ways. While there may be no right or wrong answer, ScienceBoard has initiated a long-term effort to probe experts on where they would place their bets in this epic fight. Read More
Biotools M&A scene hot in 2021
January 6, 2022 -- It was a busy year for the acquisition of biotool companies. Likewise, 2022 is expected to be another busy year for lab tool mergers and acquisitions. Read More
Virtual Biotech Showcase draws over 300 life science companies
January 5, 2022 -- Biotech Showcase is an investor conference that aims to connect global life science executives with investors. The event was scheduled to take place January 10-13, 2022, in San Francisco; however, on December 16, 2021, the event's organizers announced that it would transition to a virtual on-demand platform. Read More
Scientists develop novel tools to visualize DNA repair
January 4, 2022 -- Researchers can now visualize DNA repair in unprecedented detail using a new high-throughput microscopy technique in combination with machine learning. The methodology, published in Cell Reports on December 28, has led to the identification of new proteins involved in DNA repair. Read More
New 'armed' CAR T cells can locally activate small-molecule cancer drugs
January 3, 2022 -- A new engineered CAR T platform, which turns cells into targeted “micropharmacies” with local activation of small-molecule prodrugs, has been shown to exhibit enhanced antitumor activity and can overcome a variety of current obstacles in conventional CAR T-cell therapy. The research, conducted by Memorial Sloan Kettering Cancer Center scientists, was published in Nature Chemical Biology on December 30, 2021. Read More
BioTools Innovator

Conferences
HPLC 2022
June 18-23
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter
Latest Tweets